Revolution Medicines, Inc. provided earnings guidance for the year ended December 31, 2021. The company continued to expect that its net loss for the year ended December 31, 2021 to be between $170 million and $190 million, which includes estimated non-cash stock-based compensation expense of approximately $20 million.